The 6-Minute Walk Test and Anthropometric Characteristics as Assessment Tools in Patients with Obstructive Sleep Apnea Syndrome. A Preliminary Report during the Pandemic

Vasileios T. Stavrou 1,*, George D. Vavougios 2,3,4, Kyriaki Astara 1, Dimitra I. Siachpazidou 2, Eirini Papayianni 1 and Konstantinos I. Gourgoulianis 1

1 Laboratory of Cardio-Pulmonary Testing and Pulmonary Rehabilitation, Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece; kyriakiastara@gmail.com (K.A.); eirinipapayianni@gmail.com (E.P.); kgourg@uth.gr (K.I.G.)
2 Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece; dantevavougios@hotmail.com (G.D.V.); sidimi@windowslive.com (D.I.S.)
3 Department of Computer Science and Telecommunications, University of Thessaly, 35131 Lamia, Greece
4 Department of Neurology, Athens Naval Hospital, 11521 Athens, Greece
* Correspondence: vasileiostavrou@hotmail.com; Tel.: +30-241-350-2157

Abstract: Patients with obstructive sleep apnea syndrome (OSAS) exhibit low cardio-fitness impact, attributed to fragmented sleep architecture and associated pathophysiological sequelae. The purpose of our study was to investigate fitness indicators during 6-min walk test (6MWT) and oxidative stress markers in apnea-hypopnea index (AHI) in OSAS patients stratified by severity. A total of 37 newly diagnosed patients, comorbidity-free, were divided into two groups: (Moderate OSAS (n = 12), defined as ≥ 15 AHI < 30 events per hour; Age: 50.7 ± 7.2 years, BMI: 32.5 ± 4.0 kg/m² vs. Severe OSAS (n = 25), defined as AHI ≥ 30 events per hour; Age: 46.3 ± 10.4 years, BMI: 33.3 ± 7.9 kg/m²). Measurements included demographics, anthropometric characteristics, body composition, blood sampling for reactive oxygen metabolites’ levels (d-ROM) and plasma antioxidant capacity (PAT), and followed by a 6MWT. AHI was significantly associated with d-ROMs levels, chest circumference in maximal inhalation and exhalation (∆chest), neck circumference, as well as 6MWT-derived indices. In conclusion, our study determines bidirectional interrelationships between OSAS severity and anthropometrics, body composition, and fitness metrics. These findings indicate that the impact of OSAS should be evaluated well beyond polysomnography-derived parameters.

Keywords: sleep disorders; 6-min walk test; body composition; anthropometry; oxidative stress

1. Introduction

Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of partial or complete collapse of the upper airway during sleep, despite continuing respiratory efforts [1]. The Apnea–Hypopnea Index (AHI) is utilized to assess the severity of the syndrome among patients [2] and its severity has been associated with several comorbidity phenotypes [3]. The AHI, aligned with desaturation index (DI), reflects one of the most prominent detrimental consequence of OSAS, namely, intermittent nocturnal hypoxia. Intermittent hypoxia is responsible for increasing the risk of cardiovascular diseases, prompted by endothelial dysfunction and the production of reactive oxygen species (ROS), leading to severe pathophysiologic features that accompany OSAS [4]. The chronicity of this phenomenon enriches the clinical manifestation of OSAS with daytime clinical entities, such as arterial hypertension and neurocognitive impairment; a cascade perpetuated by several factors, like age, body mass index (BMI), and male gender [5,6]. Due to the principal role of oxidative stress in orchestrating the course of OSAS, efforts have been made to nominate the possible biomarkers for predicting the severity and the comorbidity risk in OSAS patients [7].
Among anthropometric factors, BMI and other body composition indexes play a pivotal role in OSAS, as weight gain has been associated with exacerbation of apneic episodes [8]. Neck circumference assesses cervical obesity, which has been correlated with upper airway collapsibility, making it an accurate predictor of the severity of OSAS [9]. Body fat composition is related to oxidative stress, since adipose tissue contains endocrine properties, triggering the production of ROS on an inflammatory substrate [10]. In the context of OSAS, this relationship becomes reciprocal as OSAS patients manifest both psychological and cardiorespiratory intolerance to exercise [11]. Due to the multisystemic effects of sleep disturbances, patients exhibit diminished aerobic capacity, as evaluated by cardiopulmonary exercise testing [12]. Hence, fitness indicators could potentially serve as additional predictors for OSAS severity.

The purpose of our study was to investigate associations and differences between fitness indicators captured by the 6-min walk test (6MWT), anthropometrics, body composition, oxidative stress markers, and OSAS severity, as determined via the Apnea–Hypopnea Index (AHI).

2. Materials and Methods

2.1. Study Population

A total of 37 newly diagnosed, comorbidity free OSAS patients, were included in our study. Inclusion criteria were patients presenting ≥15 events/h on the Apnea–Hypopnea Index, non-smokers, age between ≥20-to-≤65 years old, sleep duration ≥300 min during polysomnography study (PSG), without recent injury (i.e., tendinitis, muscles injuries) [13], daily physical strain due to working ≥3 h/day [14], and weekly exercise ≥100 min per week with a heart rate ≥60 % of maximum [15].

Exclusion criteria were BMI ≥ 40 kg/m² and comorbidities such as mellitus diabetes, heart failure, chronic obstructive pulmonary disease and other respiratory illness, peripheral vascular disease limiting exercise, myocardial infarction within the previous month, severe uncontrolled arrhythmia, severe and uncontrolled hypertension, severe aortic stenosis, renal failure, anemia, mental illness, and any form of musculoskeletal disability which could impair maximum exercise capacity, as per previously described protocols from our group [16].

Study Ethics

The study was approved by the Institutional Ethics Committee of University Hospital of Larissa (Ethical Committee Approval Number: 51114/04-11-19) and all participants submitted written consent according to the Helsinki declaration for use in Human subjects [17] and personal data (37/A/29-8-2019 and EC 2016/679) according to European Parliament and of the Council of the European Union.

2.2. Measurements

2.2.1. Medical History, Anthropometrics, and Questionnaires

Recorded data included complete medical history, demographics, anthropometrics [i.e., body height, chest circumference in maximal inhalation and exhalation, (Achest), waist–hip ratio (WHR)], body mass and body composition, and estimated the resting metabolic rate, total body water (Tanita MC-980, Tokyo, Japan), body mass index (BMI), and body surface area [18]. The Pittsburgh Sleep Quality Index (PSQI) [19] and Epworth Sleepiness Scale (ESS) [20] questionnaires were administered prior to the 6MWT. Historical data from previous polysomnography were also available for each patient. Sleep staging was performed via manual scoring according to the Rechtschaffen and Kales [21]. Stages 1 to 3 represent non-rapid eye movement (NREM) sleep, whereas stage 4 represents rapid eye movement sleep (REM). Pulmonary function parameters (FEV₁: forced expiratory volume in 1st sec, FVC: forced vital capacity, Master Screen-CPX, VIASYS HealthCare, Hochberg, Germany) [22] were recorded prior to data collected.
2.2.2. Oxidative Stress Markers

Blood sampling for oxidative stress measurement was performed 20 min before 6MWT. Initially, a 10 mL sample was of peripheral venous blood was collected from each patient at 08.30 a.m., having fasted the previous night. Measurements included the determination of reactive oxygen metabolites’ levels (d-ROMs test) and the plasma antioxidant capacity (PAT test) (free radical analytical system, FRAS5, Parma, Italy). Conceptually, the d-ROMs test provided an estimate of oxidative burden, whereas the PAT quantified water-soluble antioxidant contents within the same plasma sample.

2.2.3. The 6 Min Walk Test

Measurements during 6MWT [23] included arterial O$_2$ saturation (SpO$_2$) and heart rate (HR) (Ri-fox, Riester, Germany) at the following timepoints: baseline, every 1 min of test and at the 1st min of recovery. Blood pressure (BP, Mac, Tokyo, Japan) and self-assessed lower extremity fatigue with dyspnea Borg Scale CR10 [24] were recorded at the following timepoints: baseline, end of test and at the 1st min of recovery.

Additional measurements captured included total distance and peak O$_2$ uptake [25] and metabolic equivalent (METs = peak O$_2$ uptake (mL/min/kg)/3.5).

All sessions were performed in Laboratory of Cardio-Pulmonary Testing and Pulmonary Rehabilitation (University of Thessaly), with environmental temperature at 22±1°C and humidity 45±3%. The evaluation was made between 08:30 a.m. to 11:00 a.m.

2.3. Statistical Analysis

Several established cut-off points were used for data stratification. The cut-off points for oxidative stress (d-ROMs: 320 Carr.U. and PAT: 2200 U. cor.) and visceral fat (12 score) were classified according to the manufacturer’s instructions for distinguishing between healthy and border condition adults. 6MWT was set as a cross-sectional point that was 85% of the predicted value, according Ross formula [25], for distinguishing between normal and low cardiopulmonary function [26]. The neck circumference cut-off, for distinguishing between low and high priority for the overnight sleep study for suspect OSAS, was set as 40 cm [27]. An appropriate cut-off for Δchest has not be universally established, and reported associations include smoking habit, age, gender, and the co-existence of respiratory disorders [28]. Thus, a 5% difference between maximal inhalation and maximal exhalation was set as the cut off for distinguishing between well and less well enlargement of the chest cavity [29]. For continuous variables, data normality was assessed via the Kolmogorov-Smirnov test. Relationships between continuous variables were assessed via the Spearman’s Rho and Pearson’s R correlation coefficients for non-parametric and parametric variables, correspondingly. Differences between AHI strata were assessed via the independent samples $t$-test or Mann–Whitney U-test where appropriate. For all aforementioned tests, a $p$-value < 0.05 was considered statistically significant. Continuous data are presented as mean ± standard deviation (Mean ± SD). All analyses were performed via the SPSS 25 statistical package (SPSS Inc., Chicago, IL, USA).

3. Results

Table 1 presents the results of patient characteristics between two severity strata: Moderate (defined as $15 \geq$ AHI > 30 events per hour) vs. Severe OSAS (defined as AHI $\geq$ 30 events per hour). Statistically significant correlation were detected between AHI (Figure 1) and d-ROMs levels ($r = 0.360, p = 0.029$), Δchest ($r = -0.338, p = 0.041$), neck circumference ($r = 0.462, p = 0.004$), and parameters during 6MWT (Meters: $r = -0.360, p = 0.029$, estimated O$_2$ uptake: $r = -0.358, p = 0.029$, METs: $r = -0.372, p = 0.023$, Dyspnea Borg scale at the end of 6MWT: $r = 0.369, p = 0.025$). In Table 2, the cut-off points of studied variables are presented with respect to variables of polysomnography. The variabilities dROMs ($\geq 15$AHI < 30 events/h: 328.5 ± 28.9 versus AHI $\geq$ 30 events/h: 357.7 ± 15.9 U carr, $p = 0.342$, Figure 2), PAT ($\geq 15$AHI < 30 events/h: 2486.7 ± 309.7 versus AHI $\geq$ 30 events/h: 2477.3 ± 530.6 U cor, $p = 0.955$, Figure 3), anthropomet-
ric characteristics and body composition (Table 1) and fitness indicators during 6MWT (Figures 4–6), distance (≥15AHI < 30 events/h: 460.6 ± 64.9 versus AHI ≥ 30 events/h: 438.3 ± 60.1 m, p = 0.311; ≥15AHI < 30 events/h: 80.8 ± 13.7 versus AHI ≥ 30 events/h: 74.1 ± 14.3 % of predicted, p = 0.183), estimated O₂ uptake (≥15AHI < 30 events/h: 15.5 ± 1.5 versus AHI ≥ 30 events/h: 15.0 ± 1.4 mL/min/kg, p = 0.312) and metabolic equivalent (≥15AHI < 30 events/h: 4.5 ± 0.4 versus AHI ≥ 30 events/h: 4.3 ± 0.3 METs, p = 0.273) did not show differences between groups.

Table 1. Patients characteristics. Data are expressed as mean ± standard deviation.

|                      | Mean ± Sd (n = 37) | ≥15 AHI < 30 Events/h, (n = 12) | AHI ≥ 30 Events/h, (n = 25) | p Value |
|----------------------|--------------------|---------------------------------|-----------------------------|---------|
| Age, years           | 47.7 ± 9.6         | 50.7 ± 7.2                      | 46.3 ± 10.4                 | 0.194   |
| Gender, n = M/F      | 31/6               | 9/3                             | 22/3                        | -       |
| AHI, events/h⁻¹      | 48.0 ± 25.3        | 22.1 ± 5.4                      | 60.4 ± 21.2                 | <0.001  |
| Apnea, events/h⁻¹    | 17.6 ± 20.0        | 3.1 ± 3.2                       | 24.6 ± 21.0                 | 0.001   |
| Hypopnea, events/h⁻¹ | 29.0 ± 14.0        | 19.0 ± 5.1                      | 33.8 ± 14.4                 | 0.002   |
| Stage 1, %           | 4.0 ± 4.0          | 2.7 ± 0.8                       | 4.7 ± 4.8                   | 0.172   |
| Stage 2, %           | 53.9 ± 15.0        | 51.8 ± 12.0                     | 54.9 ± 16.3                 | 0.569   |
| Stage 3–4, %         | 11.0 ± 6.5         | 13.7 ± 6.7                      | 9.7 ± 6.2                   | 0.078   |
| REM, %               | 9.7 ± 5.5          | 9.6 ± 5.1                       | 9.8 ± 5.8                   | 0.923   |
| Desaturation Index, %| 51.0 ± 28.8        | 22.7 ± 9.0                      | 64.6 ± 24.7                 | <0.001  |
| Minimum SaO₂, % ‡    | 75.6 ± 12.9        | 82.7 ± 7.4                      | 72.3 ± 13.8                 | 0.020   |
| Average SaO₂, % ‡    | 87.6 ± 5.2         | 90.6 ± 1.7                      | 86.1 ± 5.7                  | 0.013   |
| Duration SaO₂ < 90%, min ‡ | 40.9 ± 51.1 | 8.8 ± 13.5                     | 56.3 ± 55.5                 | 0.006   |
| Body Mass Index, kg/m²| 33.1 ± 6.8         | 32.5 ± 4.0                      | 33.3 ± 7.9                  | 0.749   |
| Body fat, %          | 32.9 ± 9.1         | 35.2 ± 9.3                      | 31.8 ± 9.1                  | 0.303   |
| Visceral fat, score  | 14.3 ± 5.7         | 14.3 ± 4.0                      | 14.3 ± 6.4                  | 0.979   |
| Muscle mass, kg      | 34.4 ± 12.2        | 34.6 ± 13.6                     | 34.2 ± 11.7                 | 0.929   |
| Body Surface Area, m²| 2.4 ± 0.5          | 2.4 ± 0.3                       | 2.4 ± 0.6                   | 0.547   |
| Lean Body Mass, %    | 78.6 ± 6.7         | 77.3 ± 5.6                      | 79.3 ± 7.2                  | 0.415   |
| Total Body Water, %  | 49.5 ± 4.9         | 48.4 ± 4.3                      | 50.0 ± 5.2                  | 0.349   |
| RMR, kcal/day        | 1932.2 ± 269.5     | 1879.0 ± 226.1                  | 1957.8 ± 288.8              | 0.413   |
| Neck circumference, cm| 41.3 ± 4.1         | 40.3 ± 3.8                      | 41.7 ± 4.3                  | 0.340   |
| WHR                  | 0.9 ± 0.8          | 1.0 ± 0.1                       | 0.9 ± 0.1                   | 0.125   |
| Δchest, %            | 5.6 ± 2.1          | 5.5 ± 2.3                       | 5.9 ± 1.6                   | 0.628   |
| FEV₁, % of predicted | 94.9 ± 12.4        | 99.6 ± 6.1                      | 92.7 ± 14.0                 | 0.116   |
| FVC, % of predicted  | 95.8 ± 10.6        | 100.3 ± 5.5                     | 93.7 ± 11.8                 | 0.077   |
| PSQI, score          | 7.5 ± 5.2          | 8.9 ± 6.0                       | 6.8 ± 4.7                   | 0.268   |
| ESS, score           | 7.7 ± 4.5          | 6.7 ± 2.5                       | 8.1 ± 5.1                   | 0.375   |

Abbreviations: AHI: Apnea–Hypopnea Index; ESS: Epworth Sleepiness Scale; F: Female; FEV₁: forced expiratory volume in 1st sec; FVC: forced vital capacity; M: Male; PSQI: Pittsburgh Sleep Quality Index; REM: Rapid Eye Movement; RMR: resting metabolic rate; WHR: Waist-hip ratio; Δchest: chest circumference difference between maximal inhalation and exhalation. ‡ Minimum, Average and Duration of SaO₂ < 90% are polysomnography derived parameters.

Figure 1. Cont.
Figure 1. Correlation analysis results between apnea hypopnea index (AHI) and reactive oxygen metabolites’ levels (d-ROM) (a), chest circumference difference between maximal inhalation and exhalation (Δchest) (b), neck circumference (c), meters during 6 min walk test (6MWT) (d), estimated oxygen uptake (VO2) (e), metabolic equivalent (MET) (f) and dyspnea at the end of 6MWT (g).

Figure 2. Oxidative stress marker on reactive oxygen metabolites’ levels (d-ROM) between groups.

Figure 3. Oxidative stress marker on plasma antioxidant capacity (PAT) between groups.
Table 2. Comparisons between polysomnography-derived variables per subgroup. Data are presented as mean ± standard deviation.

| Subgroup | 6MWT, 65% of Predicted | p Values | NC, 40 cm | p Values | Visceral Fat, 52 Score | p Values | Achchest, 5% Differences | p Values | d-ROMs, 520 Curr.U. | p Values | PAT, 2200 U/ cor | p Values |
|----------|-------------------------|----------|-----------|----------|------------------------|----------|------------------------|----------|------------------------|----------|----------------|----------|
| n, Versus > | a ≤ 25 | a ≤ 12 | a ≤ 11 | a ≤ 26 | a ≤ 12 | a ≤ 25 | a ≤ 11 | a ≤ 24 | a ≤ 14 | a ≤ 23 | a ≤ 14 | a ≤ 23 | a ≤ 7 | a ≤ 30 |
| AHI, events/h | 53.7 ± 23 | 36.3 ± 14 | 0.048 | 32.3 ± 13 | 54.6 ± 24 | 0.012 | 37.7 ± 14 | 52.9 ± 28 | 0.087 | 59.1 ± 29 | 45.9 ± 20 | 0.047 | 37.4 ± 23 | 94.5 ± 24 | 0.044 | 61.6 ± 30 | 44.8 ± 23 | 0.117 |
| Apnea, events/h | 22.9 ± 21.5 | 6.4 ± 9.7 | 0.016 | 9.2 ± 13.2 | 21.2 ± 21.7 | 0.097 | 12.8 ± 13.9 | 20.1 ± 22.2 | 0.295 | 23.3 ± 26.7 | 15.6 ± 15.4 | 0.410 | 11.8 ± 16.9 | 21.1 ± 21.2 | 0.179 | 32.5 ± 27.2 | 14.3 ± 16.4 | 0.026 |
| Hypopnea, events/h | 28.6 ± 15.2 | 29.8 ± 11.4 | 0.017 | 23.1 ± 8.7 | 31.5 ± 15.1 | 0.096 | 25.4 ± 8.5 | 30.9 ± 15.8 | 0.251 | 35.5 ± 17.4 | 26.4 ± 11.2 | 0.120 | 25.5 ± 15.3 | 31.2 ± 12.9 | 0.235 | 29.0 ± 14.9 | 29.0 ± 14.0 | 0.995 |
| Stage 1, % | 3.4 ± 2.1 | 5.4 ± 6.9 | 0.174 | 2.9 ± 1.5 | 4.5 ± 4.7 | 0.136 | 2.8 ± 1.7 | 4.6 ± 4.7 | 0.217 | 4.2 ± 2.7 | 3.9 ± 4.7 | 0.997 | 3.3 ± 2.5 | 4.5 ± 4.8 | 0.235 | 6.9 ± 6.1 | 7.4 ± 2.1 | 0.032 |
| Stage 2, % | 58.1 ± 12.4 | 45.1 ± 16.4 | 0.011 | 55.9 ± 11.3 | 52.9 ± 16.4 | 0.088 | 56.9 ± 11.2 | 51.4 ± 16.1 | 0.154 | 53.7 ± 15.6 | 53.9 ± 14.9 | 0.967 | 52.9 ± 13.4 | 54.5 ± 16.1 | 0.365 | 47.8 ± 19.0 | 55.5 ± 13.8 | 0.241 |
| Stage 3, % | 11.0 ± 6.4 | 11.0 ± 7.1 | 0.991 | 12.6 ± 7.4 | 30.4 ± 6.5 | 0.331 | 13.0 ± 6.9 | 30.1 ± 6.3 | 0.202 | 10.3 ± 6.2 | 11.5 ± 6.8 | 0.605 | 12.2 ± 7.0 | 10.4 ± 6.3 | 0.758 | 5.4 ± 7.7 | 12.4 ± 6.0 | 0.009 |
| REM, % | 9.7 ± 4.5 | 9.8 ± 7.5 | 0.983 | 10.5 ± 4.7 | 9.4 ± 5.9 | 0.974 | 11.4 ± 3.8 | 8.9 ± 6.1 | 0.197 | 9.9 ± 4.9 | 9.6 ± 4.8 | 0.997 | 10.7 ± 5.5 | 9.1 ± 5.3 | 0.420 | 9.3 ± 6.7 | 9.8 ± 5.3 | 0.802 |
| Desaturation index, % | 55.4 ± 31.2 | 41.8 ± 21.2 | 0.066 | 31.9 ± 13.9 | 50.2 ± 28.6 | 0.038 | 36.3 ± 13.9 | 57.9 ± 31.6 | 0.032 | 67.0 ± 32.8 | 42.3 ± 22.6 | 0.010 | 57.1 ± 24.1 | 59.4 ± 28.5 | 0.398 | 69.2 ± 34.6 | 46.7 ± 26.1 | 0.062 |
| Minimum SaO₂, ‰ | 74.1 ± 14.7 | 79.6 ± 7.7 | 0.294 | 83.5 ± 7.6 | 72.4 ± 13.4 | 0.017 | 82.0 ± 8.7 | 72.6 ± 13.6 | 0.037 | 70.8 ± 15.3 | 76.2 ± 10.9 | 0.097 | 82.1 ± 8.2 | 71.7 ± 13.8 | 0.019 | 70.8 ± 14.6 | 76.9 ± 12.5 | 0.241 |
| Average SaO₂, ‰ | 87.6 ± 61 | 88.7 ± 2.4 | 0.262 | 90.5 ± 2.1 | 86.4 ± 5.7 | 0.038 | 89.9 ± 2.3 | 86.4 ± 5.9 | 0.014 | 85.5 ± 7.3 | 88.7 ± 3.4 | 0.082 | 86.9 ± 6.0 | 86.2 ± 6.0 | 0.036 | 85.1 ± 4.4 | 86.1 ± 5.5 | 0.176 |
| Duration SaO₂ < 90%, ‰ | 48.4 ± 58.5 | 25.3 ± 26.4 | 0.203 | 12.9 ± 18.2 | 52.7 ± 36.1 | 0.029 | 18.3 ± 24.2 | 51.8 ± 57.9 | 0.061 | 63.9 ± 48.5 | 28.5 ± 34.5 | 0.043 | 20.2 ± 33.3 | 51.6 ± 60.2 | 0.052 | 62.9 ± 40.2 | 39.8 ± 51.0 | 0.230 |

Abbreviations: 6MWT: 6-min walk test; AHI: Apnea Hypopnea Index; d-ROMs: reactive oxygen metabolites; n: number of patients; NC: neck circumference; PAT: plasma antioxidant capacity; REM: Rapid Eye Movement; Achchest: chest circumference difference between maximal inhalation and exhalation. † Minimum, Average and Duration of SaO₂ < 90% are polysomnography derived parameters.
According to our study design, obesity class III patients were excluded. The vicious cycle of sleep apnea perpetuated by body composition can be extracted, independently of obesity related factors [32]. Notably, body composition parameters that are not directly associated with BMI have been shown to be independently associated with the pathophysiological mechanisms underlying OSAS. As an example, increased neck circumference hinders the airway patency, a phenomenon exacerbated during sleep [33]. A measurable consequence is increasing AHI, which, when prolonged, corresponds to hypercapnia.
and the development of respiratory acidosis [34] and oxidative burden [35]. These effects are the substrate of the observable diminished physical activity and proneness to breath shortness elicited via the 6MWT. The latter furthermore corresponds to less effective chest expansion and, hence, lower VO$_2$ [36] and METs, independent of AHI severity [37]. Therefore, tools that assess fitness indicators, such as 6MWT, in conjunction with a more thorough recording of anthropometric and morphological characteristics could contribute to a more optimal characterization of OSAS patients and OSAS’ impact on their lives, while demystifying BMI.

One of the most important body composition parameters is adipose tissue. Adipose tissue encompasses several types, with visceral fat being the most clinically relevant as it is associated with more adverse effects compared to peripheral obesity [38], while there is an interrelationship between obesity and physical activity and cardiovascular diseases [39]. Moreover, visceral adipose tissue contributes to the activity of a chronic inflammatory substrate, which contributes to the underlying pathophysiology of sleep apnea [40]. Another finding of our study was that the drop in SaO$_2$ indicators during sleep are affected by anthropometric indexes and visceral fat, aside from the expected association with AHI. This finding further stress the importance of both adipose tissue and anthropometrics in understanding patient related parameters that enhance the pathophysiology of sleep disordered breathing, and may implicate alveolar implication [16,41]. The combined drive of both alveolar and upper airway dysfunction would favor the gradual onset of a hypoxic milieu gradually establishes an oxidative environment where ROS production overcomes antioxidant compensation [42].

Another significant finding of our study was the association of severe OSAS with disrupted of sleep architecture. Specifically, was assessed via the correlation of deep non-rapid eye movement (NREM, Stage 3 and 4), of relatively young patients, with PAT test. Deep NREM is fundamental for several cognitive functions, like memory consolidation [43]. Previous findings from our group have indicated that cognitive performance is affected even in younger OSAS patients, even on the subclinical level [6]. Several factors may provide the pathophysiological substrate for these relationships. Sleep disturbances disrupt microarchitecture of sleep and, thus, the circadian-related clearance of proteins related to neurodegeneration [44]. Furthermore, intermittent hypoxia and hypercapnia hampers synaptic plasticity and neuronal survival, affecting by extent several cognitive networks [45]; within the same context, neuroinflammation and oxidative stress further exacerbate this noxious milieu, setting the stage for the emergence of neurodegeneration [46,47].

**Limitations and Strengths**

The results of our study should be interpreted within the context of its limitations. Our study population was nested, and reports on patients were from a single University hospital. The University Hospital of Larisa is the referral tertiary institute for central Greece, including the mainland and several islands. Our study excluded by design class III obese patients, and, therefore, no insight can be gained from these patients. The inclusion of such a group however would require a different study design that could address the perturbations introduced by the interrelationships between class III obesity and breathing as a standalone clinical entity. Another important limitation of our study is that recruitment involved consecutive patients, and, therefore, could not provide equal size groups for, e.g., OSAS strata. We aimed to overcome this obstacle by selecting alternative stratification of our cohort using, i.e., oxidative stress and anthropometrics cut-offs, and assessing AHI differences instead.

**5. Conclusions**

The parameterization of the respiratory profile of sleep apnea through anthropometric characteristics that expand beyond body mass index might elucidate the pathophysiology of OSAS, in conjunction with body composition and fitness indicators. In this context, the
6MWT was an adequate substitute of cardiopulmonary exercise testing, when the latter was not available.

**Author Contributions:** V.T.S. and G.D.V. conceived and designed the experiments. V.T.S., D.I.S. and E.P. performed the experiments. V.T.S., K.A., E.P. and G.D.V. evaluated the data, performed the statistical analysis, and contributed to the manuscript preparation. V.T.S., K.A., G.D.V. and K.I.G. wrote and edited the paper. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research is co-financed by Greece and the European Union (European Social Fund-ESF) through the Operational Programme «Human Resources Development, Education and Lifelong Learning 2014–2020» in the context of the project «The effect of 12 weeks of supervised and self-selected exercise combined with CPAP treatment in patients with Obstructive Sleep Apnea Syndrome on the subscales of executive brain functions, 25 (OH) D levels and oxidative stress indices» (MIS 5048944).

**Institutional Review Board Statement:** The study was approved by the Institutional Ethics Committee of University Hospital of Larissa (Ethical Committee Approval Number: 51114/04-11-19).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** All data are available after request.

**Acknowledgments:** The authors would like to thank the Chaido Pastaka and George Seitanidis (Laboratory of Respiratory Sleep Disorders, Department of Respiratory Medicine, Faculty of Medicine University of Thessaly) for sleep disorders screening of patients. Moreover, the authors would like to thank the participants of this study, and acknowledge their willingness to contribute to our research effort even during the pandemic.

**Conflicts of Interest:** The authors declare they have no conflicts of interest.

**References**

1. Gottlieb, D.J.; Punjabi, N.M. Diagnosis and Management of Obstructive Sleep Apnea: A Review. *JAMA* 2020, 323, 1389–1400. [CrossRef] [PubMed]

2. Dempsey, J.A.; Veasey, S.C.; Morgan, B.J.; O'Donnell, C.P. Pathophysiology of sleep apnea. *Physiol. Rev.* 2010, 90, 47–112. [CrossRef] [PubMed]

3. Vavougios, G.D.; George, D.G.; Pastaka, C.; Zarogiannis, S.G.; Gourgoulianis, K.I. Phenotypes of comorbidity in OSAS patients: Combining categorical principal component analysis with cluster analysis. *J. Sleep Res.* 2016, 25, 31–38. [CrossRef]

4. Badran, M.; Ayas, N.; Laher, I. Cardiovascular complications of sleep apnea: Role of oxidative stress. *Oxid. Med. Cell. Longev.* 2014, 2014, 985258. [CrossRef] [PubMed]

5. Natsios, G.; Pastaka, C.; Vavougios, G.; Zarogiannis, S.G.; Tsolaki, V.; Dimoulis, A.; Seitanidis, G.; Gourgoulianis, K.I. Age, Body Mass Index, and Daytime and Nocturnal Hypoxia as Predictors of Hypertension in Patients with Obstructive Sleep Apnea. *J. Clin. Hypertens.* 2016, 18, 146–152. [CrossRef]

6. Agha, B.; Johal, A. Facial phenotype in obstructive sleep apnea-hypopnea syndrome: A systematic review and meta-analysis. *J. Sleep Res.* 2017, 26, 122–131. [CrossRef]

7. Natsios, G.; Pastaka, C.; Tsilioni, I.; Natsios, G.; Seitanidis, G.; Florou, E.; Gourgoulianis, K.I. The DJ-1 protein as a candidate biomarker in obstructive sleep apnea syndrome. *Sleep Breath.* 2014, 18, 897–900. [CrossRef]

8. Oğretmenoğlu, O.; Süslü, A.E.; Yücel, O.T.; Onerci, T.M.; Sahin, A. Body fat composition: A predictive factor for obstructive sleep apnea. *Laryngoscope* 2005, 115, 1493–1498.

9. Marsiglia, L.; Manti, S.; D’Angelo, G.; Nicotera, A.; Parisi, E.; Di Rosa, G.; Gitto, E.; Arrigo, T. Oxidative stress in obesity: A critical component in human diseases. *Int. J. Mol. Sci.* 2014, 16, 378–400. [CrossRef]

10. Chennaoui, M.; Arnal, P.J.; Sauvet, E.; Léger, D. Sleep and exercise: A reciprocal issue? *Sleep Med. Rev.* 2015, 20, 59–72. [CrossRef]

11. Stavrou, V.; Bardaka, F.; Karetsi, E.; Daniil, Z.; Gourgoulianis, K.I. Brief Review: Ergospirometry in Patients with Obstructive Sleep Apnea Syndrome. *J. Clin. Med.* 2018, 7, 191. [CrossRef]

12. Stavrou, V.T.; Astara, K.; Daniil, Z.; Gourgoulianis, K.I.; Kalabakas, K.; Karagiannis, D.; Basdekis, G. The reciprocal association between fitness indicators and sleep quality in the context of recent sport injury. *Int. J. Envir. Res. Public Health* 2020, 17, 4810. [CrossRef]

13. Stavrou, V.; Bardaka, F.; Karetsi, E.; Seitanidis, G.; Daniil, Z.; Gourgoulianis, K.I. The effect of physical strain on breeders patients with obstructive sleep apnea syndrome. *Respir. Physiol. Neurobiol.* 2019, 260, 137–139. [CrossRef]
15. Stavrou, V.; Karetsi, E.; Daniil, Z.; Gourgoulianas, K.I. 4 weeks exercise in obstructive sleep apnea syndrome patient with type 2 diabetes mellitus and without continuous positive airway pressure treatment: A case report. Sleep Med. Res. 2019, 10, 1–5. [CrossRef]

16. Stavrou, V.; Boutou, A.K.; Vavougios, G.D.; Pastaka, C.; Gourgoulianas, K.I.; Koutedakis, Y.; Daniil, Z.; Karetsi, E. The use of cardiopulmonary exercise testing in identifying the presence of obstructive sleep apnea syndrome in patients with compatible symptomatology. Respir. Physiol. Neurobiol. 2019, 262, 26–31. [CrossRef]

17. Holt, G.R. Declaration of Helsinki—The World’s Document of Conscience and Responsibility. South. Med. J. 2014, 107, 407. [CrossRef]

18. Mosteller, R.D. Simplified Calculation of Body Surface Area. N. Engl. J. Med. 1987, 317, 1098. [PubMed]

19. Buyssse, D.J.; Reynolds, C.F.; Monk, T.H.; Berman, S.R.; Kupfer, D.J. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychol. Rep. 1989, 28, 193–213. [CrossRef]

20. Johns, M.W. A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 1991, 14, 540–545. [CrossRef] [PubMed]

21. Rechtschaffen, A.; Kales, A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects; Public Health Service US Government Printing Office: Washington, DC, USA, 1968.

22. Miller, M.R.; Hankinson, J.; Brusasco, V.; Burgos, F.; Casaburi, R.; Coates, A.; Crapo, R.; Enright, P.; van der Grinten, C.P.; Gustafsson, P.; et al. ATS/ERS Task Force: Standardisation of spirometry. Eur. Respir. J. 2005, 26, 319–338. [CrossRef] [PubMed]

23. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002, 166, 111–117. [CrossRef] [PubMed]

24. Berg, E.; Berg, G.; Larsson, K.; Letzter, M.; Sundblad, B.M. An index for breathlessness and leg fatigue. Scand. J. Med. Sci. Sports 2010, 20, 644–650. [CrossRef] [PubMed]

25. Ross, R.M.; Murthy, J.N.; Wallak, I.D.; Jackson, A.S. The six minute walk test accurately estimates mean peak oxygen uptake. BMC Pulm. Med. 2010, 10, 31. [CrossRef] [PubMed]

26. Milani, R.V.; Lavie, C.J.; Mehra, M.R. Cardiopulmonary exercise testing: How do we differentiate the cause of dyspnea? Circulation 2004, 110, e27–e31. [CrossRef]

27. Ardelean, C.; Dimitriu, D.; Frent, S.; Marincu, I.; Lighezan, D.; Mihaicuta, S. Sensitivity and specificity of neck circumference in obstructive sleep apnea syndrome. Eur. Respir. J. 2014, 44, 2293.

28. Bockenhauer, S.E.; Chen, H.; Julliard, K.N.; Weedon, J. Measuring thoracic excursion: Reliability of the cloth tape measure technique. J. Am. Osteopath. Assoc. 2007, 107, 191–196.

29. Reddy, R.S.; Alahmari, K.A.; Silvian, P.S.; Ahmad, I.A.; Kakarparthi, V.N.; Rengaramanujam, K. Reliability of Chest Wall Mobility and Its Correlation with Lung Functions in Healthy Nonsmokers, Healthy Smokers, and Patients with COPD. Can. Respir. J. 2019, 25, 5175949. [CrossRef]

30. Meurling, I.J.; Shea, D.O.; Garvey, J.F. Obesity and sleep: A growing concern. Curr. Opin. Pulm. Med. 2019, 25, 602–608. [CrossRef]

31. Andreoli, A.; Garaci, F.; Cafarelli, F.P.; Guglielmi, G. Body composition in clinical practice. Eur. J. Radiol. 2016, 85, 1461–1468. [CrossRef]

32. Gines, J.; Vgontzas, A.N.; Fernandez-Mendoza, J.; Bixler, E.O. Obstructive sleep apnea and the metabolic syndrome: The road to clinically-meaningful phenotyping, improved prognosis, and personalized treatment. Sleep Med. Rev. 2018, 42, 211–219. [CrossRef]

33. Ho, M.L.; Brass, S.D. Obstructive sleep apnea. Neurology 2011, 3, e15. [CrossRef]

34. Contreras, M.; Masterson, C.; Laffey, J.G. Permissive hypercapnia: What to remember. Curr. Opin. Anaesthesiol. 2015, 28, 26–37. [CrossRef]

35. Christou, K.; Moulas, A.N.; Pastaka, C.; Gourgoulianas, K.I. Antioxidant capacity in obstructive sleep apnea patients. Sleep Med. 2003, 4, 225–228. [CrossRef]

36. Fisher, L.R.; Cawley, M.I.; Holgate, S.T. Relation between chest expansion, pulmonary function, and exercise tolerance in patients with ankylosing spondylitis. Ann. Rheum. Dis. 1990, 49, 921–925. [CrossRef]

37. Stavrou, V.T.; Astara, K.; Karetsi, E.; Daniil, Z.; Gourgoulianas, K.I. Respiratory muscle strength as an indicator of the severity of apnea hypopnea index: Stepping towards the distinction between sleep apnea and breath holding. Cureus 2021, 13, e14015. [PubMed]

38. Bonfignone, M.R.; McNicholas, W.T.; Montserrat, J.M.; Eckel, J. Adipose tissue in obesity and obstructive sleep apnoea. Eur. Respir. J. 2012, 39, 746–767. [CrossRef] [PubMed]

39. Lakka, T.A.; Bouchard, C. Physical activity, obesity and cardiovascular diseases. Atheroscler. Drug Ther. 2005, 170, 137–163.

40. Maury, E.; Ehala-Aleksjev, K.; Guiot, Y.; Detry, R.; Vandenhoof, A.; Brichard, S.M. Adipokines oversecreted by omental adipose tissue in human obesity. Am. J. Physiol. Endocrinol. Metab. 2007, 293, E656–E665. [PubMed]

41. Mateika, J.H.; Panza, G.; Alex, R.; El-Chami, M. The impact of intermittent or sustained carbon dioxide on intermittent hypoxia initiated respiratory plasticity. What is the effect of these combined stimuli on apnea severity? Respir. Physiol. Neurobiol. 2018, 256, 58–66. [CrossRef]

42. Maniaci, A.; Iannella, G.; Cocuzza, S.; Vicini, C.; Magliulo, G.; Ferlito, S.; Cammaroto, G.; Meccariello, G.; De Vito, A.; Nicolai, A.; et al. Oxidative Stress and Inflammation Biomarker Expression in Obstructive Sleep Apnea Patients. J. Clin. Med. 2021, 10, 277. [CrossRef] [PubMed]
43. Wilckens, K.A.; Ferrarelli, F.; Walker, M.P.; Buysse, D.J. Slow-Wave Activity Enhancement to Improve Cognition. *Trends Neurosci.* 2018, 41, 470–482. [CrossRef] [PubMed]

44. Wang, Y.; Mandelkow, E. Tau in physiology and pathology. *Nat. Rev. Neurosci.* 2016, 17, 22. [CrossRef] [PubMed]

45. Snyder, B.; Shell, B.; Cunningham, J.T.; Cunningham, R.L. Chronic intermittent hypoxia induces oxidative stress and inflammation in brain regions associated with early-stage neurodegeneration. *Physiol. Rep.* 2017, 5, e13258. [CrossRef] [PubMed]

46. Liu, X.; Ma, Y.; Ouyang, R.; Zeng, Z.; Zhan, Z.; Lu, H.; Cui, Y.; Dai, Z.; Luo, L.; He, C.; et al. The relationship between inflammation and neurocognitive dysfunction in obstructive sleep apnea syndrome. *J. Neuroinflamm.* 2020, 17, 229. [CrossRef]

47. Daulatzai, M.A. Pathogenesis of cognitive dysfunction in patients with obstructive sleep apnea: A hypothesis with emphasis on the nucleus tractus solitarius. *Sleep Disord.* 2012, 2012, 251096. [CrossRef]